During wound healing processes fibroblasts accounts for wound closure by adopting a contractile phenotype and produce extracellular matrix (ECM) molecules. During normal wound healing the process is terminated when the wound has healed and the initial trigger disappears. However when the trigger persists, as is the case in COPD with the repeated exposure of cigarette smoke, the wound healing process becomes pathological and the fibroblast phenotype is likely to be altered. Our aim was to investigate the repair capability, defined as ECM production and contractility, in centrally (bronchial) and distally (alveolar) derived fibroblasts from severe COPD patients and control subjects. The repair functions were different in centrally and distally derived fibroblasts from COPD patients compared to the corresponding cells from control subjects. Distally derived fibroblasts from COPD patients were more contractile and this was dependent on increased ROCK1 activity. In addition, these cells had enhanced production of the proteoglycan versican. Versican have been suggested to interfere with de novo synthesis of elastin and may thus be important in formation of emphysema. Centrally derived fibroblasts from COPD patients had a lower basal production of the basement membrane-stabilizing proteoglycan perlecan which may indicate alterations of the bronchial basement membrane in COPD. To summarize, our results suggest that fibroblasts from COPD patients have altered repair functions. Importantly, there was a difference in function between bronchial and alveolar fibroblasts which may reflect the different pathological processes in these sites.
Background: MFAP4 is a glycoprotein, co-localized with elastin and microfibrils in elastic fibres (Schlosser, Thomsen et al. (2006) ). MFAP4 knock-out mice develop mild emphysema (not yet published data). We hypothesized that circulating MFAP4 reflects elastin degradation and can be used as a marker of emphysema severity. Methods: Plasma levels of MFAP4 (pMFAP4) were determined by AlphalisaÒ assay in 76 Danish COPD patients from the multicentre ECLIPSE study, (Vestbo, Anderson et al. 2008 ) 50 smokers and 54 non-smokers. Controls were healthy blooddonors. Associations between ln-transformed pMFAP4 levels and clinical outcomes were assessed by Pearson product moment correlation test and multiple regression analysis. Age, gender, packyears and carbonmonnoxide (as a indicator of current smoking) were included as covariates.
Results: Levels of lnMFAP4 were significantly lower in smokers (mean:364ng/ mL) than in non-smokers (471 ng/mL) and COPD patients (457 ng/mL). LnMFAP4 associated significantly with MMRC (Modified Medical Research Council score) in COPD patients (b: 0.09 p<0.05). There was a tendency of association between the composite BODE index (BMI, Obstruction index, Dyspnea score and Exercise capacity), it was borderline significant when adjusting for covariates (b:0.03 p:0.07). LnpMFAP4 did not associate significantly with FEV 1 (b:-0.002 pZ0.24) or obstruction index (b:-0.004 pZ0.13). Conclusion: MFAP4 plasma levels are supressed by smoking, and are associated to dyspnea in COPD patients. References Schlosser, A., T. Thomsen, et al. (2006) . "Microfibril-associated protein 4 binds to surfactant protein A (SP-A) and colocalizes with SP-A in the extracellular matrix of the lung." Scand J Immunol 64 (2): 104-116. Vestbo J, W Anderson et al. (2008) . "Evaluation of COPD longitudinally to identify predictive surrogate end-points (ECLIPSE)." Eur Respir J 31(4): 869-873
ASSESSMENT OF LOCAL INFLAMMATION IN THE LUNGS OF SMOKERS BY HRCT
Smoking is the most important environmental risk factor for the development of COPD. Computer tomography (CT) imaging provides means of quantifying pulmonary structure and function. We hypothesized that the inflammation in smokers may be mirrored by an altered attenuation on high resolution CT (HRCT). Forty smokers with normal lung function (20 men, 20 women, age mean 54; range 45-65; 35AE12 pack years, 40 healthy neversmokers, age 57 (45-65) and 40 patients with COPD, GOLD stage I-II, age 59 (45-65) (38AE11 pack year, 31 current smokers and 9 exsmokers) underwent inspiratory HRCT scans . Values between -750 and -900 HU were considered as high attenuation areas and the percentage of the lung volume with this attenuation range was calculated. Bronchoalveolar lavage, BAL, was performed according to a standardized protocol. Cell concentration and differential cell counts in BAL fluid were recorded. The percentage of lung area with high attenuation was increased in smokers (44% AE 5.7; meanAE SD) compared to neversmokers (38% AE 5.6) and COPD exsmokers (33% AE 4.5) (p<0.001 and p<0.05 respectively) indicating denser lungs in smokers. COPD current smokers (41% AE 5.0) did not differ from that of smokers with normal lung function. A significant positive correlation (p<0.001) between cell concentration in BAL and HRCT areas with high density was found in current smokers. There was no significant correlation between cell concentrations in BAL and HRCT density in neversmokers and COPD exsmokers. Female neversmokers had denser lungs than males (40% AE 1.3 vs 36% AE1.3, pZ0.03). This was also the case for smokers with normal lung function (females 46% AE 1.3 vs males 42% +1.2; p<0.04). The increased density in smokers compared to nonsmokers may mirror an inflammatory response induced by cigarette smoke and is correlated to current smoking status rather than smoking history. This hypothesis is strengthened by a positive correlation between lung attenuation and cell concentration in the lower respiratory tract. A gender difference was found suggesting a more intense inflammation in female smokers than in males.
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